Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 11, 2025

Costco (COST) Q1 2026 Earnings Call Transcript

View original at nasdaq.com
Costco (COST) Q1 2026 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, Dec. 11, 2025 at 5 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Long-term geographic target is approximately 50% US and 50% international across Canada, Mexico, Europe, Asia, and Australia

    80% confidence

  • AI pharmacy inventory system improved in-stock levels to >98% with mid-teens script fill growth

    80% confidence

  • Personalization system launched in Q1 showed positive sales lift

    80% confidence

  • Extended operating hours for executive members generated estimated ~1% sales lift

    80% confidence

  • Renewal rate may still see a slight decline over next few quarters due to digitally-signed members with lower renewal rates

    80% confidence

  • Excluding tax benefits, net income and EPS grew 13.6% year-over-year in Q1 2026

    80% confidence

  • Q1 was the first quarter where healthcare costs grew at faster pace than sales, creating SG&A headwinds

    80% confidence

  • Kirkland Signature is growing faster than overall sales with 15-20% value proposition vs national brands

    80% confidence

  • Executive membership upgrades saw a 'nice uptick' from extended hours and Instacart benefits

    80% confidence

  • FY2025 warehouse openings are achieving $192M annualized productivity per warehouse vs $150M for FY2023 openings

    80% confidence

  • Warehouse relocations typically generate 20-60% sales uplift

    80% confidence

  • Targeted communications to expiring digitally-signed members showing early success in improving renewal rates

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Costco (COST) Q1 2026 Earnings Call Transcript — Source | Via News | ViaNews EU